Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Giardia Lamblia Infections in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinical symptoms could be explained by giardiasis AND~* fecal samples will test positive for the presence of G.lamblia in Uusimaa laboratory (HUSLAB)~Exclusion Criteria:~* age \<6 mo or \>10 years~* weight \<9.5 kg~* the absence of symptoms~* co-infection with another pathogen, which may cause giardiasis-like symptoms

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Metronidazole (Type: EXPERIMENTAL): Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those weighing 30-44,9 kg. Suppositories will not be halved. Patients will be given 1 dose/day for 3 days.
- Tinidazole (Type: ACTIVE_COMPARATOR): Patients will be treated with a standard regimen of oral tinidazole (Fasigyn) at a single dose of 50 mg/kg, maximum 2 g/dose

Based on this trial design, predict the completion outcome and termination type (if applicable).